Killing effect of interleukin-13 receptor alpha 2 (IL-13Ralpha2) sensitized DC-CTL cells on human glioblastoma U251 cells.
Recent studies show that IL-13Ralpha2, a brain tumor-associated antigen for IL-13, may play a role in immunotherapy for glioblastoma. Thus, we stimulated the lymphocyte by monocyte-derived dendritic cells (DCs). The DCs were pulsed with IL-13Ralpha2 in vitro and then co-cultured with lymphocytes. After inducing cytotoxic T cells (CTLs) and co-culturing with U251 cells for 24 h in 96 wells, Cell Count Kit-8 (CCK-8) was added to every well equally. The optical density (OD) value was detected and recorded after 2 h. The DCs efficiently presented the antigen to the CTLs, resulting in CTLs activation and proliferation. The induced CTLs showed specific cytotoxic against U251 cells (P<0.01). The results demonstrated that IL-13Ralpha2 induced CTLs could kill glioma U251 in vitro, which suggests that IL-13 Ralpha2 might have such an impact in vivo and thus recombinant IL-13Ra2 protein might be used as an anti-tumor vaccine, providing a promising new strategy for the treatment of brain malignant gliomas.
Yan
Xinjiang
X
Department of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou 325000, China.
Su
Zhipeng
Z
Zhang
Jing
J
Wu
Zhebao
Z
Ye
Sheng
S
Lu
Xianghe
X
Wu
Jinsen
J
Zeng
Yanjun
Y
Zheng
Weiming
W
D001932:Brain Neoplasms; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000276:immunology*; D005909:Glioblastoma; D006801:Humans; D053663:Interleukin-13 Receptor alpha2 Subunit / Q000276:immunology*; D008213:Lymphocyte Activation / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000166:cytology* / Q000276:immunology*
D053663:Interleukin-13 Receptor alpha2 Subunit